Yayın: Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study
| dc.contributor.author | Gülbaş, Zafer | |
| dc.contributor.author | В Я Мельниченко | |
| dc.contributor.author | Krimo Bouabdallah | |
| dc.contributor.author | Jan Walewski | |
| dc.contributor.author | Alejandro Majlis | |
| dc.contributor.author | Laura Maria Fogliatto | |
| dc.contributor.author | Dolores Caballero | |
| dc.contributor.author | Beth Christian | |
| dc.contributor.author | Zafer Gülbaş | |
| dc.contributor.author | Muhıt Özcan | |
| dc.contributor.author | Gilles Salles | |
| dc.contributor.author | Margaret A. Shipp | |
| dc.contributor.author | Seth Thompson | |
| dc.contributor.author | Robert Orlowski | |
| dc.contributor.author | Patricia Marinello | |
| dc.contributor.author | Philippe Armand | |
| dc.contributor.orcid | 0000-0002-2112-2651 | |
| dc.contributor.orcid | 0000-0002-6728-6264 | |
| dc.contributor.orcid | 0000-0002-4425-7823 | |
| dc.contributor.orcid | 0000-0003-4247-2674 | |
| dc.contributor.orcid | 0000-0002-0610-7971 | |
| dc.contributor.orcid | 0000-0002-4709-0627 | |
| dc.contributor.orcid | 0000-0002-1326-1918 | |
| dc.contributor.orcid | 0000-0002-9541-8666 | |
| dc.contributor.orcid | 0000-0002-3949-6897 | |
| dc.contributor.orcid | 0000-0002-8037-9932 | |
| dc.contributor.orcid | 0000-0001-6098-1603 | |
| dc.date.accessioned | 2025-11-13T20:32:35Z | |
| dc.date.issued | 2020-11-04 | |
| dc.identifier.doi | https://doi.org/10.1182/blood-2020-137080 | |
| dc.identifier.endpage | 43 | |
| dc.identifier.issn | 0006-4971 | |
| dc.identifier.issue | Supplement 1 | |
| dc.identifier.openalex | W3095491461 | |
| dc.identifier.startpage | 42 | |
| dc.identifier.uri | https://hdl.handle.net/11421/12148 | |
| dc.identifier.uri | https://doi.org/10.1182/blood-2020-137080 | |
| dc.identifier.volume | 136 | |
| dc.language.iso | en | |
| dc.relation.ispartof | Blood | |
| dc.rights | restrictedAccess | |
| dc.subject | Refractory (planetary science) | |
| dc.subject | Medicine | |
| dc.subject | Pembrolizumab | |
| dc.subject | Internal medicine | |
| dc.subject | Oncology | |
| dc.subject | Cancer | |
| dc.subject | Immunotherapy | |
| dc.subject | Materials science | |
| dc.subject.sdg | 3 | |
| dc.title | Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.authorid.openalex | A5058571002 |
